Jump to content

Coeliac disease

From Surgopaedia

Gluten-sensitive enteropathy

Pathogenesis:

[edit | edit source]
  • Autoimmune disorder triggered by gluten in genetically-predisposed individuals

Clinical manifestations

[edit | edit source]
  • Classic symptoms related to malabsorption:
    • Diarrhoea
    • Steatorrhoea
    • Weight loss
    • Nutrient or vitamin deficiencies
  • Majority have only minor GIT complaints
  • Associated conditions:
    • Dermatitis herpetiformis (grouped intensely pruritic papules and vesicles, mostly on elbows, dorsal forearms, knees, scalp, back and buttocks)
    • Atrophic glossitis
    • Metabolic bone disease
    • Iron deficiency anaemia (UTD says coeliac disease is found in up to 10% of patients presenting for investigation of IDA)
    • Selective IgA deficiency
    • Other conditions with autoimmune components
    • Increased risk for lymphoma and GIT cancer (unclear if the incidence of cancer is affected by good management of coeliac disease)

Risk factors:

[edit | edit source]
  • First and second degree relative with confirmed coeliac disease
  • T1DM
  • Autoimmune thyroiditis
  • Down and Turner syndromes
  • Pulmonary haemosiderosis

Investigation:

[edit | edit source]
  • Serologic tests
    • Tissue transglutaminase-IgA is the single preferred test
    • Serum tissue transglutaminase IgA and endomysial IgA have similar sensitivities
    • Sensitivity depends on severity of disease
    • Tests may become negative within weeks of adherence to gluten-free diet
    • Positive serology generally mandates a small bowel biopsy to confirm diagnosis
    • Serologic tests can give a false negative in: IgA deficiency, gluten-free diet, and mild disease
  • Gastroscopy with small bowel biopsy
    • Look for:
      • Atrophic appearing mucosa with loss of folds
      • Visible fissures
      • Nodularity
      • Scalloping
      • Prominent submucosal vascularity
      • However, endoscopic visual features alone have a low sensitivity (60-90%)
      • Features can also be seen with giardiasis, autoimmune enteropathy, and HIV infection
    • Biopsy:
      • At least four biopsies of post-bulbar duodenum
      • Some advocate for bulb biopsies too, but these are probably not necessary, and if taken should be sent separately and labelled as such to avoid the false-positive finding of villous atrophy on those samples
      • I don't THINK it makes a difference whether they are on gluten for that part

Diagnosis

[edit | edit source]
  • Diagnostic criteria:
    • Duodenal biopsy samples showing increased intraepithelial lymphocytes with crypt hyperplasia or also with villous atrophy, in a patient with positive coeliac serology
  • Patients on a gluten-containing diet:
    • Low disease probability (absence of symptoms or signs of malabsorption such as chronic diarrhoea/steatorrhoea or weight loss; absence of family history; chinese, japanese or sub-saharan african descent)
      • Serologic testing
        • Negative test for an individual with low risk of coeliac disease has a high negative predictive value and obviates the need for small bowel biopsy
      • If positive, gastroscopy with small bowel biopsy
    • High disease probability (clinical presentation highly suggestive for coeliac disease, such as chronic diarrhoea/steatorrhoea with weight loss; both risk factors and consistent symptoms/signs)
      • Both serologic testing and small bowel biopsy
  • Patients on a gluten-free diet
    • Do serologic testing anyway
    • If negative, do HLA-DQ2/DQ8 testing
      • If negative coeliac disease excluding
      • If positive, give them gluten for 8 weeks then repeat serology and small bowel biopsy
  • Positive serology and nondiagnostic biopsies:
    • False-positive tTg - see UTD
    • False-negative biopsy - can have a patchy distribution or initially be confined to duodenal bulb
    • Can do further tests like HLA-DQ2/DQ8 genotyping - would refer to gastro, I guess
  • Negative serology and abnormal small bowel biopsy
    • Genetic testing
    • If positive, gluten free diet for 12-24 months and monitor clinical response